A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This study is a prospective, single-center, open, single-arm, exploratory study to evaluate
the safety and efficacy of 177Lu-EB-FAPI PRRT, and to explore 177Lu-EB-FAPI in patients with
advanced pancreatic cancer and cholangiocarcinoma. Eligible patients with advanced pancreatic
cancer or cholangiocarcinoma were screened and enrolled after signing the informed consent
forms. In the first stage of the enrolled patients, the 177Lu-EB-FAPI treatment dose was
determined using a 3 + 3 dose escalation mode. Patients enrolled in the second phase, divided
into pancreatic cancer cohort and cholangiocarcinoma based on pathology, will receive the
first phase determined dose of 177Lu-EB-FAPI every 4 weeks, and each patient will receive no
more than 4 cycles. The aim of the study is to evaluate the safety and efficacy of the
177Lu-EB-FAPI treatment.